• Skip to primary navigation
  • Skip to main content
  • Skip to footer

TVM Capital Life Science Venture Capital

Investing in Life Science Innovation

  • About Us
    • Partners
  • Team
  • Senior Advisors
  • Portfolio
  • Funding Request
  • News
  • Events
  • ESG Policy
  • Contact

T7 Therapeutics

  • Home
  • About Us
  • Team
  • Senior Advisors
  • Portfolio
  • News
  • Events
  • ESG Policy
  • Contact

T7 Therapeutics

Investment: 2021
Visit Website

T7 Therapeutics plans to develop, a first-in-class monoclonal antibody targeting a broad set of autoimmune diseases to clinical proof-of-concept. This antibody targets a new critical pathway in autoimmunity, initially discovered by Nalân Utku during her training at the laboratories in Renal Division of Brigham and Women’s Hospital, Harvard Medical School. Humanized antibodies subsequently were developed at Nekonal S.a.r.l.

  • in

Copyright © 2023 · TVM Capital Life Science Venture Capital · ESG Disclosure · Privacy Policy · Contact